PartnershipJun 25, 2026, 06:16 AM
Cordyceps Sunshine Biotech Secures Exclusive Antcin A Platform Rights
AI Summary
Cordyceps Sunshine Biotech Holdings Co., Ltd. (Party B) has entered into a Cooperation and Development Agreement with Pet Sunshine Biological Research Co., Ltd. (Party A) for the Antcin A Platform. Under the agreement, Cordyceps Sunshine Biotech receives exclusive worldwide rights for the development, commercialization, licensing, and capital market development of the Antcin A platform, which is positioned as a "Next-Generation Non-Steroidal Anti-Inflammatory Drug Platform." The agreement outlines a 50/50 split of commercial revenues and grants Cordyceps Sunshine Biotech preemptive rights and a right of first refusal regarding the platform assets.
Key Highlights
- Cordyceps Sunshine Biotech granted exclusive worldwide rights for Antcin A platform.
- Antcin A platform positioned as "Next-Generation Non-Steroidal Anti-Inflammatory Drug Platform."
- Platform assets include all Antcin A core technologies, data, IP, and commercialization rights.
- Antcin A Platform Products include TFA-01 and future derivative products.
- Cordyceps Sunshine Biotech will solely manage global commercialization, licensing, and capital market development.
- Commercial revenues from the Antcin A platform will be shared 50/50 between the parties.
- Cordyceps Sunshine Biotech holds preemptive rights and right of first refusal for platform assets.
Price Impact
More from RAJAF